HI-Bio
Guorui (Grace) Xie is a Senior Scientist specializing in Biomarker/Translational Immunology at HI-Bio, a Biogen Company, since October 2024. Prior to this role, Guorui Xie held positions as Scientist II and Scientist I at RAPT Therapeutics from August 2021 to July 2024. Guorui Xie also completed a postdoctoral fellowship at Gladstone Institutes from November 2015 to August 2021. Guorui Xie earned a PhD in Immune response to West Nile virus infection from The University of Texas Medical Branch in 2015, following a bachelor's degree from Shandong Normal University in 2007.
This person is not in any teams
HI-Bio
HI-Bio was established on the premise that treatments for immune-mediated illnesses have the potential to provide patients with better outcomes. Many IMDs are caused by immune system cells, such as mast cells, neutrophils, plasma cells, and more, which are dysfunctional. These cells are in charge of crucial processes and functions. With the useof medicines, HI-efforts Bio uses a precision medicine strategy to target, modify or deplete key cellular disease drivers.HI-Bio was established in 2021 in San Francisco, California.